In an exciting development for the pharmaceutical industry, AQEMIA, a pioneering next-generation pharmatech company, has successfully raised an impressive $65 million in its latest funding round. Specializing in cutting-edge drug discovery, AQEMIA aims to revolutionize the way we combat critical diseases, including challenging areas like immuno-oncology. Their innovative approach utilizes unique quantum and statistical mechanics algorithms to power a generative artificial intelligence capable of designing novel drug candidates without relying on traditional experimental data. This groundbreaking technology has already led to significant successes in their internal pipeline and collaborations with key pharmaceutical companies, with advanced programs currently progressing into in vivo optimization.
The funding will allow AQEMIA to accelerate its development efforts, enhance its proprietary algorithms, and expand its collaborative network within the pharmaceutical industry. With an ambitious goal to create fast, innovative drug candidates, this new capital injection highlights the growing confidence in AQEMIA’s vision and capabilities in reshaping drug discovery.
Moreover, this funding round supports AQEMIA's expansion plans, including the recruitment of top talent committed to driving their mission forward. We invite interested candidates to explore exciting career opportunities at AQEMIA on our career website: https://jobs.lever.co/aqemia.com. For a glimpse into the vibrant culture and roles within our organization, check out our Welcome to the Jungle page at https://www.welcometothejungle.com/fr/companies/aqemia. Stay tuned for more updates on our journey, and join us as we continue to innovate and redefine the future of medicine! For in-depth insights, don’t forget to follow our blog at https://medium.com/aqemia.
.png&w=3840&q=75)
